On May 30, 2025, Titan Pharmaceuticals issued a total of 415,000 shares of common stock following the conversion of Series AA and Series B Preferred Stock by Sire Group and Blue Harbour. The conversions took place after requests on May 13, 2025, resulting in 150,087 shares for Sire Group and 265,913 shares for Blue Harbour.